FRS2 and urinary bladder cancer: Phospho-ERKand phospho-STAT5 are also reduced with the same concentration dependence,consistent with potent suppression of FGFR activation by the inhibitor.Treatment of the bladder cancer line RT-4 that harbors anFGFR3-TACC3 translocation [19] with INCB054828 strongly suppresseslevels of phospho-FRS2, a scaffolding protein that is a substrate of FGFR, andphospho-ERK (Fig 2B).